Promise Sermorelin Reviews: Visits Are Paused, So Old Prices Need Caution

What the live page says now

The Promise sermorelin page says visits are paused during a move to a new prescriber network. It labels the treatment as coming soon and offers an email notification form. The page explicitly distinguishes that form from a medical request or prescription.

We did not verify a reopening date or a current purchasable price. An educational description of the medicine remains on the page, but it should not be mistaken for evidence that a clinician can assess a new request today.

For that reason, Promise is included in our availability watchlist rather than the active-provider ranking. The review can help readers understand what to recheck later without suggesting that an unavailable service is a current treatment option.

Why we are not repeating the indexed prices

Search results and cached page versions still contain monthly and quarterly amounts. The live page has changed. We have excluded those amounts from the current comparison because an old offer does not establish what will be available when the service reopens.

This is a practical example of the difference between finding a price and verifying an offer. A search snippet may be useful for discovering a provider, but the current product page, applicable terms, and eventual checkout need to agree before a number becomes a reliable purchasing reference.

Our introductory and renewal price guide covers another version of the same problem: a prominent number can describe only one stage of a purchase. Here the unresolved issue comes earlier, because visits themselves are paused.

A waitlist does not reserve clinical care

An email notification may tell you that a service has changed status. It does not establish eligibility, a scheduled appointment, a prescription, or a dispensing commitment. Read the purpose of the form before submitting information and do not treat it as a substitute for an assessment.

If you already receive care elsewhere, do not build a refill plan around an unconfirmed reopening. Discuss continuity with your existing clinician. We have not verified any transfer arrangement or priority access for people who join Promise's waitlist.

The Pallas review offers a different comparison: an advertised program with a specific age policy and renewal interval. These are different access situations, not evidence that one service's medicine is more effective.

The network transition leaves specific questions

When visits resume, ask which clinical organization will assess you, which clinician is responsible for prescribing, and which pharmacy will dispense any prescription. Older legal or marketing references should not be assumed to identify the final arrangements after a network change.

The Promise terms describe separate platform, clinical, and pharmacy roles. That distinction is useful background, but we have not verified that every older named relationship will govern a future sermorelin order.

A clear new offer should also explain how questions reach the care team, whether outside records are needed, and how follow-up is scheduled. Request those details for the reopened program rather than assembling a care plan from several dated pages.

Rebuild the budget when the offer returns

Ask for the amount charged at enrollment, any charge after approval, the recurring interval, and the services included. If a supply period is stated, confirm that it describes the actual prescription rather than a general product example.

Promise's terms say the price and billing conditions presented when ordering govern the purchase. They also describe optional subscriptions and conditions around refunds. Those general provisions do not supply a missing current quote or prove that an older subscription configuration will return unchanged.

Keep clinical decisions separate from financial requests. If treatment is inappropriate, ask what assessment or records may still be useful; ask the billing service separately what happens to any authorized payment. Neither outcome should be guessed from a waitlist page.

What the educational material can establish

The page describes an intended injectable offering and an assessment before prescribing. Those are descriptions of the planned process, not independently verified patient outcomes or a pharmacy-quality assessment by this publication.

The FDA's compounding overview explains that compounded medicines are not FDA-approved. If a program resumes, ask about the exact preparation and evidence relevant to your goal. Do not infer that another peptide linked on the same website is interchangeable with sermorelin.

We have not reviewed a dispensed product, tested response times, or observed a clinical visit. This article also has not been independently reviewed by a clinician. Its main verified finding is the current pause and the resulting limit on a price comparison.

Our assessment today

Promise is a service to monitor, not an active purchase recommendation as of this check. The useful trigger for revisiting the review is a live clinical enrollment route with confirmed terms, rather than another search result containing an old price.

For currently advertised alternatives, start with the CoreAge Rx review and Pallas comparison, then confirm eligibility directly. A provider list should make unavailable access visible, even when that means leaving a price field unresolved.